RE:RE:RE:Updated prezzie Yes, it would be hard to justify not trying the only available treatment that might save a patient's life. And, as you say, there will also be Canadian sales and EAA sales.
$3B USD seems conservative. And if you use that 20X EBITDA you ends up with a
$22 CAD stock price.
mercedesman wrote: NP
For your target, all you need is 50% market penetration assumption
( not sure how Docs could ignore a potentially life saving approved treatment with legal liability concerns in the US?)
Or if you prefer a more realistic EBITDA multiple like say 20X +
I won't do the math if you get both !!
MM
PS I like to think worldwide EAA sales ( assuming post gold seal of approval from FDA) and Cdn sales will add 20% to the targets.